معرفی
June Helen Myklebust is an Associate Professor at the Institute for Cancer Research, Faculty of Medicine, University of Oslo. Her research focuses on B-cell lymphoma, cancer immunology, and tumor microenvironment with particular emphasis on B-cell receptor signaling and germinal center biology. She maintains a strong research presence at Oslo University Hospital Radiumhospitalet where she conducts laboratory research and collaborates with clinical teams.
Dr. Myklebust's primary research interests include:
- Mechanisms of B-cell receptor signaling in lymphoma
- Tumor microenvironment and immune interactions in B-cell malignancies
- Development of novel immunotherapies including CAR T-cell approaches
- Genomic and molecular characterization of lymphoma subtypes
- Understanding mechanisms of transformation in indolent lymphomas
Analysis of her recent publications reveals a strong focus on translational cancer research with emphasis on B-cell lymphoma biology. Her work spans from basic molecular mechanisms of B-cell signaling to clinical applications of immunotherapy. A significant portion of her research investigates how tumor cells interact with the immune system, particularly focusing on T cell exhaustion and regulatory mechanisms within the tumor microenvironment. Her laboratory employs advanced techniques including single-cell profiling, mass cytometry, and genomic analysis to understand lymphoma heterogeneity and evolution.
Dr. Myklebust maintains an active research program with numerous collaborations both nationally and internationally. Her work has appeared in high-impact journals including Blood, Cancer Cell, and Nature family journals, demonstrating the significance of her contributions to the field of lymphoma research.
She is actively involved in mentoring researchers and collaborating with clinical teams to translate basic research findings into potential therapeutic approaches for lymphoma patients. Her laboratory work focuses on understanding the molecular mechanisms driving lymphomagenesis and identifying novel therapeutic targets.
